Active — Not RecruitingNot Applicable

Effectiveness of Xenogenic Collagen Matrix in Modification of Mucosal Phenotype Around Dental Implants

Egypt20 participantsStarted 2025-10-01

Plain-language summary

Aim of the study The rationale for conducting the present study is to evaluate the efficacy of porcine collagen matrix in the management of defective width of keratinized mucosa around dental implant.

Who can participate

Age range

25 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patient between 25-50 years old.
. Remaining bone height of more than 8 mm, remaining bone width of 6 mm
. Inadequate keratinized soft tissue \<2 mm (13).
. Favorable pattern of occlusion.
. Good oral hygiene.
. Patient ability to comply with the required recall visits.

Exclusion criteria

. Insufficient bone width (less than 6 mm) mesiodistal or buccolingually.
. Patients having any uncontrolled systemic disease which could affect bone healing.
. Patients treated with radiotherapy to the head and neck area within the past 12 months.
. Heavy Smokers (more than 20 cigarette per day) according to WHO.
. Inability or unwillingness to return for follow-up visits.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Clinical Evaluation:

Timeframe: 3 months

clinical

Timeframe: 3 months

Clinical

Timeframe: 3 months

clinical

Timeframe: 3 months

Trial details

NCT IDNCT07577193

SponsorMansoura University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-09-28

View on ClinicalTrials.gov More Soft Tissue Atrophy trials

Who can participate

Age range

25 Years – 50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Patient between 25-50 years old.
. Remaining bone height of more than 8 mm, remaining bone width of 6 mm
. Inadequate keratinized soft tissue \<2 mm (13).
. Favorable pattern of occlusion.
. Good oral hygiene.
. Patient ability to comply with the required recall visits.

Exclusion criteria

. Insufficient bone width (less than 6 mm) mesiodistal or buccolingually.
. Patients having any uncontrolled systemic disease which could affect bone healing.
. Patients treated with radiotherapy to the head and neck area within the past 12 months.
. Heavy Smokers (more than 20 cigarette per day) according to WHO.
. Inability or unwillingness to return for follow-up visits.